Home Biosimilar Antibodies Transmembrane Transporters CD markers Daratumumab (anti-CD38)
For research use only. Not for use in humans.

Daratumumab (anti-CD38)

Synonyms: ADP-ribosyl cyclase 1， T10

Daratumumab (anti-CD38) is a recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug which is indicated for the treatment of adult patients with multiple myeloma. MW =145.4 kDa.

Daratumumab (anti-CD38)

Click to purchase the isotype control of Daratumumab (anti-CD38)

4 Citations

The Nobel Prize

17 Nobel Prize winners have used Selleck products

Shimon Sakaguchi

Nature Communications 2025,16, Article number:1325

David Baker

Dev Cell 2023, 58(20):2163-2180.e9.

David Julius

Cell 2017, 185-198.e16

Michael Houghton

Cell Chem Biol, 2020, 27(7):780-792.e5

Charles M. Rice

Cell 2018, 172(3):423-438.e25

Quality Control

Batch: A202701 Purity: 98.74% Protein concentration: 5.09mg/ml Endotoxin Level: ≤1 EU/mg
98.74

Specificity

Name Citation CD38 CD45 CD39 CD88 CD73 Others
RBN013209 0
MK-0159 0
CD38 inhibitor 1 (compound 78c) 7
AB680 1
NQ301 1 TXA2 receptor
SodiuM Metatungstate 3
PMX-53 3
LY-3475070 2
Expand to Check More
1. "+" indicates inhibitory effect. Increased inhibition is marked by a higher "+" designation. 2. "✔" indicates inhibitory effect, but without specific value.

Mechanism of Action

Description
Daratumumab (anti-CD38) is a recombinant monoclonal antibody to CD38. Daratumumab is an investigational anti-cancer drug which is indicated for the treatment of adult patients with multiple myeloma. MW =145.4 kDa.

Product Details

CAS No. 945721-28-8
Isotype Human IgG1
Source Human
Sterility 0.2 μM filtered
Formulation PBS Buffer, PH 7.4
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles

Comparison of Clones for

*Literature analysis of various clone (for this target) products available on the market shows that Selleck's selected clones are more frequently applied. (data until September 2024)

Clinical Trial Information

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT06358638 RECRUITING Drug: Daratumumab|Drug: Alemtuzumab|Drug: Sirolimus Sickle Cell Disease Children's National Research Institute 2024-04-03 PHASE2
NCT07095452 RECRUITING Drug: Etentamig|Drug: Lenalidomide|Drug: Daratumumab|Drug: D Multiple Myeloma AbbVie 2026-01-08 PHASE2; PHASE3
NCT07428369 WITHDRAWN Drug: Linvoseltamab|Drug: Bortezomib|Drug: Lenalidomide|Drug Multiple Myeloma (MM) Regeneron Pharmaceuticals 2026-06-05 PHASE2; PHASE3
NCT06932562 RECRUITING Drug: Linvoseltamab|Drug: Daratumumab|Drug: Lenalidomide|Dru Multiple Myeloma European Myeloma Network B.V. 2025-12-23 PHASE3
NCT06918002 RECRUITING Drug: Elranatamab|Drug: Lenalidomide (Revlimid®)|Drug: Darat Multiple Myeloma, Newly Diagnosed Intergroupe Francophone du Myelome 2025-07-09 PHASE3
NCT06892522 RECRUITING Drug: Etentamig|Drug: Lenalidomide|Drug: Dexamethasone|Drug: Multiple Myeloma AbbVie 2025-06-30 PHASE1; PHASE2

(data from https://clinicaltrials.gov, updated on 2025-09-26)

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.